Page last updated: 2024-11-12

bxl628

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

BXL628: a calcitriol analog for Inhibition of prostate cell growth; in phase II clinical trial in patients with benign prostate hyperplasia (4/2004) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID11396600
SCHEMBL ID12932254
MeSH IDM0467610

Synonyms (27)

Synonym
(1r,3z,5s)-3-[(2e)-2-[(3as,7as)-1-[(e,2s)-6-ethyl-6-hydroxyoct-4-en-2-yl]-7a-methyl-3a,5,6,7-tetrahydro-3h-inden-4-ylidene]ethylidene]-5-fluoro-4-methylidenecyclohexan-1-ol
1alpha-fluoro-16-ene-20-epi-23-ene-26,27-bishomo-25-hydroxyvitamin d3
gtpl2785
bxl-628
ro-26-9228
elocalcitol
bxl628
199798-84-0
2wds5f2v6q ,
bxl 628
cyclohexanol, 3-((1-(5-ethyl-5-hydroxy-1-methyl-3-heptenyl)-3,3a,5,6,7,7a-hexahydro-7a-methyl-4h-inden-4-ylidene)ethylidene)-5-fluoro-4-methylene-, (3as-(1(1r*,3e),3aalpha,4e(1s*,3z,5r*),7abeta))-
unii-2wds5f2v6q
cyclohexanol, 3-((2e)-((3as,7as)-1-((1s,3e)-5-ethyl-5-hydroxy-1-methyl-3-heptenyl)-3,3a,5,6,7,7a-hexahydro-7a-methyl-4h-inden-4-ylidene)ethylidene)-5-fluoro-4-methylene-, (1r,3z,5s)-
elocalcitol [inn]
ro 26-9228
1alpha-fluoro-25-hydroxy-16,23e-diene-26,27-bishomo-20-epi-cholecalciferol
1s,3r,5z,7e,23e)-1-fluoro-26,27-dihomo-9,10-secocholesta-5,7,10(19),16,23-pentaene-3,25-diol
elocalcitol [mart.]
SCHEMBL12932254
(1r,5s,z)-3-((e)-2-((3as,7as)-3-((s,e)-6-ethyl-6-hydroxyoct-4-en-2-yl)-3a-methyl-3a,4,5,6-tetrahydro-1h-inden-7(7ah)-ylidene)ethylidene)-5-fluoro-4-methylenecyclohexanol
AKOS025312296
DB06194
Q27077174
ZHA79884
CS-0001526
HY-32345
E98793

Research Excerpts

Treatment

ExcerptReferenceRelevance
"BXL628 treatment reduced serum MMCP1 levels, indicating an effect on mast cell degranulation in vivo."( Oral treatment with a vitamin D3 analogue (BXL628) has anti-inflammatory effects in rodent model of interstitial cystitis.
Andersson, KE; Baroni, E; Benigni, F; Colli, E; D'Ambrosio, D; Hedlund, P; Streng, T; Zecevic, M; Zvara, P, 2006
)
1.32

Dosage Studied

ExcerptRelevanceReference
" For IC(50) determination and comparison, dose-response curves with VDR agonists, tacrolimus and mycophenolic acid were performed."( Comparison between VDR analogs and current immunosuppressive drugs in relation to CXCL10 secretion by human renal tubular cells.
Adorini, L; Borgogni, E; Crescioli, C; Mazzinghi, B; Romagnani, P; Sagrinati, C; Serio, M; Sottili, M, 2010
)
0.36
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1346762Rat Vitamin D receptor (1I. Vitamin D receptor-like receptors)2002Endocrinology, May, Volume: 143, Issue:5
Cellular and molecular events associated with the bone-protecting activity of the noncalcemic vitamin D analog Ro-26-9228 in osteopenic rats.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (31)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's20 (64.52)29.6817
2010's11 (35.48)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (6.06%)5.53%
Reviews5 (15.15%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other26 (78.79%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]